射波刀技术及其在前列腺癌治疗中的应用

CyberKnife technology and its application in the treatment of prostate cancer

摘要

前列腺癌是全球男性常见的恶性肿瘤之一，其治疗目标是在有效控制肿瘤的同时，最大限度地保证患者的生活质量。随着医学影像和放射治疗技术的飞速发展，立体定向放射治疗和放射外科已成为前列腺癌治疗的重要手段。射波刀作为一种先进的影像引导式无框架放射治疗系统，以其独特的实时影像跟踪、自动补偿技术和高度精细的剂量塑形能力，在前列腺癌的精准治疗中展现出显著优势。本综述旨在回顾射波刀技术在前列腺癌治疗中的应用现状，重点探讨其剂量学优势、临床疗效、毒副作用以及与其他治疗方式的比较，并展望其未来的发展方向。

Abstract

Prostate cancer is one of the most common malignant tumors among males worldwide, and its treatment objective is to effectively control the tumor while maximally preserving patient's quality of life. With the rapid advancement of medical imaging and radiotherapy technologies, stereotactic body radiotherapy and radiosurgery have become important modalities in prostate cancer management. As an advanced frameless, image-guided radiotherapy system, CyberKnife demonstrates significant advantages in the precise treatment of prostate cancer, owing to its unique capabilities in real-time image tracking, automatic compensation, and highly conformal dose shaping. This review summarizes the current applications of CyberKnife technology in prostate cancer treatment, focusing on its dosimetric advantages, clinical efficacy, treatment-related toxicities, and comparisons with other treatment modalities. In addition, future development prospects are discussed.

关键词

射波刀 / 前列腺癌 / 立体定向放射治疗 / 剂量学 / 临床应用 / 综述

Key words

CyberKnife / prostate cancer / stereotactic body radiotherapy / dosimetry / clinical application / review

参考文献

[1] Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263.

[2] 陈赟, 赵改书, 李成, 等 . 前列腺癌主要治疗方法及不良反应的比较[J]. 中国老年保健医学, 2019, 17(3): 99-100.

[3] Chen Y, Zhao GS, Li C, et al. Comparison of main treatment methods and adverse reactions for prostate cancer[J]. Chinese Journal of Geriatric Care, 2019, 17(3): 99-100.

[4] Yekedüz E, Utkan G, Kanesvaran R, et al. Expanding armamentarium in advanced prostate cancer management: are all novel antiandrogens the same?[J]. Prostate Int, 2021, 9(1): 1-5.

[5] Murgić J, Fröbe A, Kiang Chua ML . Recent advances in radiotherapy modalities for prostate cancer[J]. Acta Clin Croat, 2022, 61(S3): 57-64.

[6] 郭召 . 立体定向放射治疗设备的技术现状及发展趋势[J]. 中国医疗设备, 2024, 39(9): 144-149.

[7] Guo Z. Technical status and development trend of stereotactic radiotherapy equipment[J]. China Medical Devices, 2024, 39(9): 144-149.

[8] Nguyen P, Harzée L, Retif P, et al. Prospective validation of stringent dose constraints for prostatic stereotactic radiation monotherapy: results of a single—arm phase II toxicity—oriented trial[J]. Strahlenther Onkol, 2021, 197(11): 1001-1009.

[9] Aghdam N, Pepin A, Carrasquilla M, et al. Self—reported burden in elderly patients with localized prostate cancer treated with stereotactic body radiation therapy (SBRT)[J]. Front Oncol, 2020, 9: 1528.

[10] Vuolukka K, Auvinen P, Tiainen E, et al. Stereotactic body radiotherapy for localized prostate cancer—5—year efficacy results[J]. Radiat Oncol, 2020, 15(1): 173.

[11] Kim HJ . Clinical outcome of stereotactic body radiotherapy for localized prostate cancer: long—term results[J]. Int J Radiat Res, 2020, 18: 383-388.

[12] 叶淑华, 林伟, 石鑫, 等 . M6型射波刀的基本原理与平板探测器故障维修一例[J]. 医疗装备, 2023, 36(9): 85-87.

[13] Ye SH, Lin W, Shi X, et al. Basic principles of the CyberKnife M6 and a case study of flat—panel detector failure maintenance[J]. Medical Equipment, 2023, 36(9): 85-87.

[14] 麻亚茹 . 膀胱和肠道准备对前列腺癌放疗精准实施和受照剂量的影响[D]. 广州: 南方医科大学, 2025.

[15] Ma YR . Influence of bladder and bowel preparationon the precise delivery and radiation dose in prostate cancer radiotherapy[D]. Guangzhou: Southern Medical University, 2025.

[16] Kon M, Okamoto H, Nakamura S, et al. Planning study: prone versus supine position for stereotactic body radiotherapy in prostate by CyberKnife [J]. J Radiat Res, 2023, 64(1): 186-194.

[17] 胡立宏, 程瑞, 张倩, 等 . 射波刀技术现状与发展及其临床应用[J]. 医疗卫生装备, 2015, 36(3): 110-112.

[18] Hu LH, Cheng R, Zhang Q, et al. Present situation, development and clinical application of CyberKnife[J]. Chinese Medical Equipment Journal, 2015, 36(3): 110-112.

[19] Manabe Y, Hashimoto S, Mukouyama H, et al. Stereotactic body radiotherapy using a hydrogel spacer for localized prostate cancer: a dosimetric comparison between tomotherapy with the newly—developed tumor—tracking system and CyberKnife[J]. J Appl Clin Med Phys, 2021, 22(10): 66-72.

[20] Borzillo V, Scipilliti E, Pezzulla D, et al. Stereotactic body radiotherapy with CyberKnife® System for low—and intermediate—risk prostate cancer: clinical outcomes and toxicities of CyPro Trial[J]. Front Oncol, 2023, 13: 1270498.

[21] Krug D, Imhoff D, Haidenberger A, et al. Robotic stereotactic body radiotherapy for localized prostate cancer: final analysis of the German HYPOSTAT trial[J]. Strahlenther Onkol, 2023, 199(6): 565-573.

[22] Yasar B, Suh YE, Chapman E, et al. Simultaneous focal boost with stereotactic radiation therapy for localized intermediate— to high—risk prostate cancer: primary outcomes of the SPARC phase 2 trial[J]. Int J Radiat Oncol Biol Phys, 2024, 120(1): 49-58.

[23] Nicholls L, Suh YE, Chapman E, et al. Stereotactic radiotherapy with focal boost for intermediate and high—risk prostate cancer: initial results of the SPARC trial[J]. Clin Transl Radiat Oncol, 2020, 25: 88-93.

[24] 中华医学会放射肿瘤治疗学分会, 中国核学会近距离与智慧放疗分会, 上海医学会肿瘤放射治疗分会, 等 . 射波刀治疗前列腺癌专家共识[J]. 中华转移性肿瘤杂志, 2025, 8(2): 150-157.

[25] Chinese Society for Therapeutic Radiation Oncology, Brachytherapy and Intelligent Radiosurgery Division of Chinese Nuclear Society, Tumor Radiotherapy Branch of Shanghai Medical Association, et al. Expert consensus on the treatment of prostate cancer by CyberKnife[J]. Chinese Journal of Metastatic Cancer, 2025, 8(2): 150-157.

[26] Milecki P, Adamska A, Rucinska A, et al. Large prostate volume does not negatively impact health—related quality of life in patients with prostate cancer treated with ultrahypofractionated stereotactic body radiotherapy[J]. J Pers Med, 2023, 13(2): 233.

[27] Nakamura R, Hirata T, Suzuki O, et al. Stereotactic body radiotherapy using CyberKnife®for localized low—and intermediate—risk prostate cancer: initial report on a phase I/II trial[J]. Anticancer Res, 2020, 40(4): 2053-2057.

[28] Miszczyk M, Rembak—szynkiewicz J, Magrowski Ł, et al. The prognostic value of PI—RADS score in CyberKnife ultra—hypofractionated radiotherapy for localized prostate cancer[J]. Cancers (Basel), 2022, 14(7): 1613.

[29] Ratnakumaran R, Brand DH, Sasitharan A, et al. Exploring factors associated with late urinary toxicity after prostate stereotactic body radiotherapy: findings from the PACE—B study[J]. Eur Urol, 2026, 89(1): 71-79.

[30] Pasquier D, Peiffert D, Nickers P, et al. A multicenter phase 2 study of hypofractionated stereostatic boost in intermediate risk prostate carcinoma: a 5—year analysis of the CKNO—PRO trial[J]. Int J Radiat Oncol Biol Phys, 2020, 106(1): 116-123.

[31] Pasquier D, Nickers P, Peiffert D, et al. A multicenter phase 2 study of ultrahypofractionated stereotactic boost after external beam radiotherapy in intermediate—risk prostate carcinoma: a very long—term analysis of the CKNO—PRO trial[J]. Eur Urol Open Sci, 2023, 54: 80-87.

[32] Schröder C, Mose L, Mathier E, et al. Five fractions versus seven fractions SBRT for intermediate— and high—risk prostate cancer: a propensity score matched pair analysis [J]. Cancers (Basel), 2023, 15(24): 5815.

[33] Zhao XZ, Ye YS, Yu HY, et al. Five—year outcomes of stereotactic body radiation therapy (SBRT) for prostate cancer: the largest experience in China[J]. J Cancer Res Clin Oncol, 2021, 147(12): 3557-3564.

[34] Kim HJ . Long—term outcome of whole pelvis radiotherapy and stereotactic body radiotherapy boost for intermediate and high risk prostate cancer[J]. Int J Radiat Res, 2022, 20: 37-41.

[35] Shah S, Pepin A, Forsthoefel M, et al. Testosterone as a biomarker for quality of life (QOL) following androgen deprivation therapy (ADT) and stereotactic body radiotherapy (SBRT)[J]. Cureus, 2023, 15(8): e44440.

[36] Kim YJ, Ahn H, Kim CS, et al. Phase I/IIa trial of androgen deprivation therapy, external beam radiotherapy, and stereotactic body radiotherapy boost for high—risk prostate cancer (ADEBAR)[J]. Radiat Oncol, 2020, 15(1): 234.

[37] Van Dams R, Jiang NY, Fuller DB, et al. Stereotactic body radiotherapy for High—Risk localized carcinoma of the prostate (SHARP) consortium: analysis of 344 prospectively treated patients[J]. Int J Radiat Oncol Biol Phys, 2021, 110(3): 731-737.

[38] Francolini G, Carnevale MG, Di cataldo V, et al. Stereotactic reirradiation with CyberknifeR for locally recurrent prostate cancer, long—term toxicity and clinical outcomes from a monocentric cohort[J]. Radiol Med, 2023, 128(12): 1580-1588.

[39] Allali S, Loap P, Bibault JE, et al. Salvage stereotactic reirradiation for intraprostatic cancer recurrence: a large retrospective study[J]. Prostate, 2023, 83(8): 743-750.

[40] Koh MJ, Pilkington P, Koh MJ, et al. Safety and early efficacy of involved—field SBRT for nodal oligo—recurrent prostate cancer[J]. Front Oncol, 2024, 14: 1434504.

[41] Majewski W, Miszczyk M, Graupner D, et al. Stereotactic body radiotherapy (SBRT) re—irradiation for local failures following radical prostatectomy and post—operative radiotherapy[J]. Strahlenther Onkol, 2024, 200(3): 230-238.

[42] Francolini G, Loi M, Di Cataldo V, et al. Stereotactic re—irradiation in recurrent prostate cancer after previous postoperative or definitive radiotherapy: long—term results after a median follow—up of 4 years[J]. Clin Oncol (R Coll Radiol), 2022, 34(1): 50-56.

[43] Kearney T, Nagel L, Bourne M, et al. Timing and patterns of potentially salvageable recurrences following stereotactic body radiation therapy for clinically localized prostate cancer assessed by preferential amino acid uptake[J]. Cureus, 2025, 17(1): e77964.

[44] Xu CY, Zhao XZ, Ju XP, et al. Short—term outcomes and clinical efficacy of stereotactic body radiation therapy (SBRT) for oligometastases of prostate cancer in China[J]. Front Oncol, 2022, 12: 879310.

[45] 沈泽天, 周含, 季晓芹, 等 . 射波刀立体定向放射治疗在前列腺癌肝转移中的应用[J]. 中华男科学杂志, 2019, 25(4): 333-339.

[46] Shen ZT, Zhou H, Ji XQ, et al. CyberKnife stereotactic body radiotherapy for liver metastases from prostate cancer[J]. National Journal of Andrology, 2019, 25(4): 333-339.

[47] 傅华, 田种泽, 李莎, 等 . 射波刀治疗前列腺癌合并骨转移疗效分析[J]. 局解手术学杂志, 2018, 27(11): 843-845.

[48] Fu H, Tian ZZ, Li S, et al. CyberKnife for treatment of bone metastases from prostate cancer[J]. Journal of Regional Anatomy and Operative Surgery, 2018, 27(11): 843-845.

[49] Van Werkhoven LA, Milder MT, Hoogeman MS, et al. Results of a single—arm phase 2 clinical trial: online adaptive stereotactic body radiation therapy for abdominal—pelvic oligometastases[J]. Int J Radiat Oncol Biol Phys, 2025, 122(3): 729-738.

[50] Gaudian K, Koh MJ, Koh MJ, et al. Late radiation—related lymphopenia after prostate stereotactic body radiation therapy plus or minus supplemental pelvic irradiation[J]. Front Oncol, 2024, 14: 1459732.

[51] Galienne M, Risbourg S, Lacornerie T, et al. Extreme hypofractionated stereotactic radiotherapy for localized prostate cancer: efficacy and late urinary toxicity according to transurethral resection of the prostate history[J]. Clin Transl Radiat Oncol, 2024, 46: 100779.

[52] Shah S, Sholklapper T, Creswell M, et al. Bothersome hematospermia following stereotactic body radiation therapy for prostate cancer[J]. Front Oncol, 2021, 11: 765171.

[53] Sholklapper T, Creswell M, Cantalino J, et al. Ejaculatory function following stereotactic body radiation therapy for prostate cancer[J]. J Sex Med, 2022, 19(5): 771-780.

[54] Ito M, Takahashi H, Suzuki J, et al. Intravesical prostatic protrusion as a predictor of acute urinary retention following stereotactic body radiation therapy for localised prostate cancer:a retrospective study[J]. Oncologie, 2025, 27(6): 909-917.

[55] Ito M, Yoshioka Y, Takase Y, et al. Stereotactic body radiation therapy for prostate cancer: a study comparing 3—year genitourinary toxicity between CyberKnife and volumetric—modulated arc therapy by propensity score analysis[J]. Radiat Oncol, 2023, 18(1): 39.

[56] Serra M, De Martino F, Savino F, et al. SBRT for localized prostate cancer: CyberKnife vs. VMAT—FFF, a dosimetric study [J]. Life (Basel), 2022, 12(5): 711.

[57] Borowicz DM, Skrobała A, Kruszyna—Mochalska M, et al. Does CyberKnife improve dose distribution versus IMRT and VMAT on a linear accelerator in low—risk prostate cancer? [J]. Radiol Oncol, 2022, 56(2): 259-266.

[58] Ratnakumaran R, Sasitharan A, Khan A, et al. Dosimetric comparison of CyberKnife and conventional linac prostate stereotactic body radiation therapy plans: analysis of the PACE—B study[J]. Int J Radiat Oncol Biol Phys, 2026, 125(1): 250-256.

[59] Gagliardo G, Serra M, Ametrano G, et al. Evaluating dosimetric outcomes: a comparison of CyberKnife, VMAT FFF, and Helical tomotherapy radixact for treating localized prostate cancer[J]. Radiol Med, 2025, 130(10): 1680-1692.

[60] Serra M, Ametrano G, Borzillo V, et al. Dosimetric comparison among CyberKnife, helical tomotherapy and VMAT for hypofractionated treatment in localized prostate cancer[J]. Medicine (Baltimore), 2020, 99(50): e23574.

[61] Nahaji I, Fröhlich G, Mavrogenis S, et al. Early effects of different irradiation techniques used in the treatment of prostate cancer on urination[J]. Orv Hetil, 2021, 162(33): 1328-1334.

[62] Aghdam N, Pepin A, Buchberger D, et al. Stereotactic body radiation therapy (SBRT) for prostate cancer in men with a high baseline international prostate symptom score (IPSS≥15)[J]. Front Oncol, 2020, 10: 1060.

[63] Huang HF, Gao XX, Li Q, et al. Dosimetric comparison between stereotactic body radiotherapy and carbon—ion radiation therapy for prostate cancer[J]. Quant Imaging Med Surg, 2023, 13(10): 6965-6978.

[64] Li C, Guo Y, Lin X, et al. Deep reinforcement learning in radiation therapy planning optimization: a comprehensive review[J]. Phys Med, 2024, 125: 104498.

[65] Yoganathan SA, Riyas M, Sukumaran R, et al. Ultra—hypofractionated prostate radiotherapy with online adaptive technique: a case report[J]. Cureus, 2024, 16(7): e64101.

[66] Schipaanboord BW, Giżyńska MK, Rossi L, et al. Fully automated treatment planning for MLC—based robotic radiotherapy[J]. Med Phys, 2021, 48(8): 4139-4147.

[67] Annagiri S, Hori YS, Persad AR, et al. Global growth and distribution of CyberKnife stereotactic radiosurgery: a bibliometric analysis[J]. Neurosurg Pract, 2025, 6(3): e000150.

[68] Scholey J, Nano T, Singhrao K, et al. Linac— and CyberKnife—based MRI—only treatment planning of prostate SBRT using an optimized synthetic CT calibration curve[J]. J Appl Clin Med Phys, 2024, 25(9): e14411.

[69] Francolini G, Bertini N, Di cataldo V, et al. Impact of stereotactic body radiotherapy after progression in castrate resistant prostate cancer patients undergoing first line abiraterone treatment. A subgroup analysis from ARTO trial (NCT03449719)[J]. Prostate Cancer Prostatic Dis, 2025, 28(4): 908-912.

[70] Brand VJ, Milder MT, Christianen ME, et al. First—in—men online adaptive robotic stereotactic body radiation therapy: toward ultrahypofractionation for high—risk prostate cancer patients[J]. Adv Radiat Oncol, 2025, 10(2): 101701.

基金资助

国家自然科学基金(82473233)

国家自然科学基金(82272742)

上海卫生健康委员会领军人才计划(2022LJ019)

长海医院“固海”计划(GH145-33)